Abstract
The vascular endothelial growth factor (VEGF) is a key regulator of neovascularization and an elevated level of VEGF is known to correlate with increased metastatic invasion. Anti-angiogenic therapies focus on targeted inhibition of overexpressed growth factors with the aim of suppressing tumor proliferation, one approach is the attempt to block the intracellular tyrosine kinase at the adenosine triphosphate (ATP) binding site with small molecule inhibitors. For most effective treatment these targeted tumor therapies are accompanied with a more sensitive need for dose optimization and monitoring the therapeutic response. Direct non-invasive molecular imaging of tumor vascularization and of the angiogenic process in vivo would facilitate the selection of patients and help to evaluate the efficacy of an anti-angiogenic therapy. Radionuclide-based imaging technologies like PET and SPECT are progressively affecting the clinical diagnosis and treatment of cancer. A non-invasive and a reliable quantitative method to determine in vivo the levels of VEGFR expression using radiolabeled small molecules would help to develop a customized VEGFR-targeted chemotherapy. This review will give an overview on radiolabeled derivatives of small molecule VEGFR inhibitors basing on lead structures that have been approved or have reached clinical trials. It is covering aspects of the radiosynthesis as well the results of radiopharmacological and biological evaluation.
Keywords: Anti-angiogenic, tumor therapy, VEGFR, PET, tyrosine kinase inhibitors, radiolabeling, neovascularization, tumor proliferation, SPECT, clinical trials
Current Pharmaceutical Design
Title:Radiolabeled Small Molecule Inhibitors of VEGFR - Recent Advances
Volume: 18 Issue: 20
Author(s): Torsten Kniess
Affiliation:
Keywords: Anti-angiogenic, tumor therapy, VEGFR, PET, tyrosine kinase inhibitors, radiolabeling, neovascularization, tumor proliferation, SPECT, clinical trials
Abstract: The vascular endothelial growth factor (VEGF) is a key regulator of neovascularization and an elevated level of VEGF is known to correlate with increased metastatic invasion. Anti-angiogenic therapies focus on targeted inhibition of overexpressed growth factors with the aim of suppressing tumor proliferation, one approach is the attempt to block the intracellular tyrosine kinase at the adenosine triphosphate (ATP) binding site with small molecule inhibitors. For most effective treatment these targeted tumor therapies are accompanied with a more sensitive need for dose optimization and monitoring the therapeutic response. Direct non-invasive molecular imaging of tumor vascularization and of the angiogenic process in vivo would facilitate the selection of patients and help to evaluate the efficacy of an anti-angiogenic therapy. Radionuclide-based imaging technologies like PET and SPECT are progressively affecting the clinical diagnosis and treatment of cancer. A non-invasive and a reliable quantitative method to determine in vivo the levels of VEGFR expression using radiolabeled small molecules would help to develop a customized VEGFR-targeted chemotherapy. This review will give an overview on radiolabeled derivatives of small molecule VEGFR inhibitors basing on lead structures that have been approved or have reached clinical trials. It is covering aspects of the radiosynthesis as well the results of radiopharmacological and biological evaluation.
Export Options
About this article
Cite this article as:
Kniess Torsten, Radiolabeled Small Molecule Inhibitors of VEGFR - Recent Advances, Current Pharmaceutical Design 2012; 18 (20) . https://dx.doi.org/10.2174/138161212800672796
DOI https://dx.doi.org/10.2174/138161212800672796 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
Current Radiopharmaceuticals Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Current Drug Targets EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology Preoperative Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS)
Current Medical Imaging Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research Regulatory T Cells: Major Players in the Tumor Microenvironment
Current Pharmaceutical Design 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry A Comparative Study of Two Novel Nanosized Radiolabeled Analogues of Methionine for SPECT Tumor Imaging
Current Medicinal Chemistry Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development
Current Cancer Drug Targets Farnesylated Proteins as Anticancer Drug Targets: From Laboratory to the Clinic
Current Medicinal Chemistry - Anti-Cancer Agents Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets T2/FLAIR Hyperintensity in Mesial Temporal Lobe: Challenging Differential Diagnosis
Current Medical Imaging Methods of Preparation of Multifunctional Microbubbles and their In Vitro / In Vivo Assessment of Stability, Functional and Structural Properties
Current Pharmaceutical Design The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets